Gene panels have been a part of cBioPortal for some time but were not yet incorporated in the patient view. The Hyve has now implemented support for gene panels in the patient view, to allow users to distinguish between alterations that were not[…]
The Hyve has implemented treatment support data support in cBioPortal, which has been included in the recently released 3.1.0 version of the platform. This will allow researchers to correlate drug response with genetic alterations, helping them in[…]
The cBioPortal community and The Hyve have always championed Open Source and Open Data. Now that the FAIR principles for data stewardship are gaining momentum, we cannot stay behind! To take a small step towards FAIR compliance, rich metadata[…]
Last month we enjoyed the privilege of joining the latest cBioPortal hackathon, this time hosted by MSKCC at the New York Genome Center and counting with the participation of The Hyve, Dana Farber, Princess Margaret Cancer Centre and Children's[…]
The cBioPortal for Cancer Genomics has recently incorporated a new feature developed by The Hyve which allows for visualization of the Fraction of Genome Altered or the Total Mutations in the Plots tab.
The Hyve recently added gene set scoring visualization to cBioPortal OncoPrint. To give you an example, we created our own instance that has the TCGA glioblastoma dataset loaded with gene sets identified by Roel Verhaak and colleagues. Using the[…]
The Hyve recently developed visualization for germline mutations in cBioPortal OncoPrint. This feature was sponsored by AstraZeneca and has been shared with the community on www.cbioportal.org and on cBioPortal GitHub. Use case Inherited[…]
The OncoPrint view in cBioPortal is a user friendly visualization for genetic alterations. All types of data from a cancer genomic study are integrated in the OncoPrint view: in one overview you can see mutations, expression levels and copy number[…]
One of the key challenges in cancer research is to find patients that will respond well to targeted drug therapy. Specific mutations in a patient’s tumor can be an indication of the patient’s potential responsiveness to such therapy.